Literature DB >> 20014280

Analysis of nifedipine absorption from soft gelatin capsules using PBPK modeling and biorelevant dissolution testing.

Kirstin Thelen1, Ekarat Jantratid, Jennifer B Dressman, Jörg Lippert, Stefan Willmann.   

Abstract

Delayed absorption of nifedipine when administered as a 20 mg immediate release soft gelatin capsule to fasted volunteers has been reported. Physiologically based pharmacokinetic (PBPK) modeling and in vitro dissolution data were used to explore our hypothesis that at high doses of nifedipine it precipitates in the stomach. Plasma concentration-time profiles following different doses of nifedipine were simulated using commercial PBPK software and compared to in vivo data. In vitro dissolution tests were performed with Adalat 10 mg capsules in different volumes of fasted state simulated gastric fluid (FaSSGF). The discrepancy in plasma concentration-time profiles between the different nifedipine doses could be well simulated, assuming protracted dissolution for the 20 mg dose. Nifedipine release from one Adalat 10 capsule in 250 or 500 mL FaSSGF was completed within 15 min whereas when release from two capsules, corresponding to 20 mg nifedipine, was studied in 250 mL FaSSGF, a maximum of about 75% drug dissolved was observed after 15 min followed by a decline in the % dissolved to a final value of approximately 40%. Based on the in silico and in vitro results it can be concluded that the observed prolongation in nifedipine absorption following the 20 mg dose was likely caused by nifedipine precipitation in human stomach. (c) 2009 Wiley-Liss, Inc. and the American Pharmacists Association

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20014280     DOI: 10.1002/jps.22026

Source DB:  PubMed          Journal:  J Pharm Sci        ISSN: 0022-3549            Impact factor:   3.534


  5 in total

1.  Solution behavior of PVP-VA and HPMC-AS-based amorphous solid dispersions and their bioavailability implications.

Authors:  Feng Qian; Jennifer Wang; Ruiling Hartley; Jing Tao; Raja Haddadin; Neil Mathias; Munir Hussain
Journal:  Pharm Res       Date:  2012-10       Impact factor: 4.200

2.  Effect of Gastric Fluid Volume on the In Vitro Dissolution and In Vivo Absorption of BCS Class II Drugs: a Case Study with Nifedipine.

Authors:  Ahmed M Nader; Sara K Quinney; Hala M Fadda; David R Foster
Journal:  AAPS J       Date:  2016-04-22       Impact factor: 4.009

3.  Prediction of a potentially effective dose in humans for BAY 60-5521, a potent inhibitor of cholesteryl ester transfer protein (CETP) by allometric species scaling and combined pharmacodynamic and physiologically-based pharmacokinetic modelling.

Authors:  Olaf Weber; Stefan Willmann; Hilmar Bischoff; Volkhart Li; Alexandros Vakalopoulos; Klemens Lustig; Frank-Thorsten Hafner; Roland Heinig; Carsten Schmeck; Klaus Buehner
Journal:  Br J Clin Pharmacol       Date:  2012-02       Impact factor: 4.335

4.  A STELLA simulation model for in vitro dissolution testing of respirable size particles.

Authors:  Basanth Babu Eedara; Ian G Tucker; Shyamal C Das
Journal:  Sci Rep       Date:  2019-12-06       Impact factor: 4.379

5.  Building in-house PBPK modelling tools for oral drug administration from literature information.

Authors:  Silvia Grandoni; Nicola Cesari; Giandomenico Brogin; Paola Puccini; Paolo Magni
Journal:  ADMET DMPK       Date:  2019-02-23
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.